Cargando…

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2) are drugs that have been reported to have several effects through the regulation of plasma volume, for example, antihypertensive effects. This study aimed to clarify the impact of long‐term administration and subsequent discontinuation of the SGLT2 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubayashi, Yasuhiro, Yoshida, Akihiro, Suganami, Hideki, Oe, Momoko, Sato, Takaaki, Yaguchi, Yuta, Fujihara, Kazuya, Yamada, Takaho, Tanaka, Shiro, Kaku, Kohei, Sone, Hirohito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252731/
https://www.ncbi.nlm.nih.gov/pubmed/33769665
http://dx.doi.org/10.1111/dom.14387
_version_ 1783717361942003712
author Matsubayashi, Yasuhiro
Yoshida, Akihiro
Suganami, Hideki
Oe, Momoko
Sato, Takaaki
Yaguchi, Yuta
Fujihara, Kazuya
Yamada, Takaho
Tanaka, Shiro
Kaku, Kohei
Sone, Hirohito
author_facet Matsubayashi, Yasuhiro
Yoshida, Akihiro
Suganami, Hideki
Oe, Momoko
Sato, Takaaki
Yaguchi, Yuta
Fujihara, Kazuya
Yamada, Takaho
Tanaka, Shiro
Kaku, Kohei
Sone, Hirohito
author_sort Matsubayashi, Yasuhiro
collection PubMed
description Sodium‐glucose cotransporter‐2 inhibitors (SGLT2) are drugs that have been reported to have several effects through the regulation of plasma volume, for example, antihypertensive effects. This study aimed to clarify the impact of long‐term administration and subsequent discontinuation of the SGLT2 inhibitor tofogliflozin on estimated plasma volume (ePV), brain natriuretic peptide (BNP) and the relationship between changes in ePV, BNP and body weight (BW). Data from 157 participants with type 2 diabetes receiving tofogliflozin monotherapy in a phase 3 study were analysed. Changes in variables or correlations among them during a 52‐week administration and a 2‐week post‐treatment period were investigated. Percent change in ePV was calculated using the Strauss formula. Significant decreases in BW, ePV and ln‐transformed BNP (ln‐BNP) were noted by week 52. %ΔBW was not significantly correlated with %ΔePV and Δln‐BNP, while %ΔePV was significantly correlated with Δln‐BNP. Two weeks after discontinuation of tofogliflozin, BW, ePV and ln‐BNP were significantly increased. %ΔBW was significantly correlated with %ΔePV and Δln‐BNP. Furthermore, ePV and BNP were significantly higher than baseline levels.
format Online
Article
Text
id pubmed-8252731
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-82527312021-07-12 Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin Matsubayashi, Yasuhiro Yoshida, Akihiro Suganami, Hideki Oe, Momoko Sato, Takaaki Yaguchi, Yuta Fujihara, Kazuya Yamada, Takaho Tanaka, Shiro Kaku, Kohei Sone, Hirohito Diabetes Obes Metab Brief Reports Sodium‐glucose cotransporter‐2 inhibitors (SGLT2) are drugs that have been reported to have several effects through the regulation of plasma volume, for example, antihypertensive effects. This study aimed to clarify the impact of long‐term administration and subsequent discontinuation of the SGLT2 inhibitor tofogliflozin on estimated plasma volume (ePV), brain natriuretic peptide (BNP) and the relationship between changes in ePV, BNP and body weight (BW). Data from 157 participants with type 2 diabetes receiving tofogliflozin monotherapy in a phase 3 study were analysed. Changes in variables or correlations among them during a 52‐week administration and a 2‐week post‐treatment period were investigated. Percent change in ePV was calculated using the Strauss formula. Significant decreases in BW, ePV and ln‐transformed BNP (ln‐BNP) were noted by week 52. %ΔBW was not significantly correlated with %ΔePV and Δln‐BNP, while %ΔePV was significantly correlated with Δln‐BNP. Two weeks after discontinuation of tofogliflozin, BW, ePV and ln‐BNP were significantly increased. %ΔBW was significantly correlated with %ΔePV and Δln‐BNP. Furthermore, ePV and BNP were significantly higher than baseline levels. Blackwell Publishing Ltd 2021-05-04 2021-07 /pmc/articles/PMC8252731/ /pubmed/33769665 http://dx.doi.org/10.1111/dom.14387 Text en © 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Reports
Matsubayashi, Yasuhiro
Yoshida, Akihiro
Suganami, Hideki
Oe, Momoko
Sato, Takaaki
Yaguchi, Yuta
Fujihara, Kazuya
Yamada, Takaho
Tanaka, Shiro
Kaku, Kohei
Sone, Hirohito
Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
title Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
title_full Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
title_fullStr Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
title_full_unstemmed Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
title_short Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
title_sort association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252731/
https://www.ncbi.nlm.nih.gov/pubmed/33769665
http://dx.doi.org/10.1111/dom.14387
work_keys_str_mv AT matsubayashiyasuhiro associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT yoshidaakihiro associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT suganamihideki associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT oemomoko associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT satotakaaki associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT yaguchiyuta associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT fujiharakazuya associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT yamadatakaho associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT tanakashiro associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT kakukohei associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin
AT sonehirohito associationofestimatedplasmavolumeandweightlossafterlongtermadministrationandsubsequentdiscontinuationofthesodiumglucosecotransporter2inhibitortofogliflozin